Drug intelligence / Profile preview

GENEVAX-HIV

Development stage: Phase 1
Lead developer: Pfizer
Modality: DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics
Administration: Intramuscular, Intradermal

Overview

GENEVAX-HIV (APL-400-003) is a candidate DNA vaccine developed for the prevention of HIV infection. It is designed to induce an immune response against HIV in seronegative individuals and has been evaluated in pilot studies using intramuscular or intradermal administration. The vaccine utilizes DNA technology to stimulate the body's immune system to recognize and respond to HIV antigens, aiming to provide protective immunity against the virus. It is being developed by Pfizer.

Other names: GENEVAX-HIV

Targets

HIV-1 antigens

Beyond the preview

Go deeper on GENEVAX-HIV.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GENEVAX-HIV.

Explore the full profile